Objective To analyze the treatment effect of alprostadil combined with insulin glargine in diabetic nephropa-thy.Methods The clinical data of 120 patients with diabetic nephropathy admitted to the 73rd Group Army Hospital of the People's Liberation Army of China from January 2023 to March 2024 were retrospectively selected and divided into two groups according to different therapeutic drugs,60 cases in each group.The control group was treated with methyl-prednisolone combined with insulin glargine,and the study group was treated with alprostadil combined with insulin glargine.The blood glucose levels(fasting blood glucose,2-hour postprandial blood glucose),renal function(urea nitro-gen,creatinine,24-hour h urine protein)and clinical efficacy were compared between the two groups.Results Before treatment,there were no significant difference in levels of blood glucose and renal function between the two groups(all P>0.05).After treatment,the levels of blood glucose and renal function in the study group were lower than those in the control group,and the differences were statistically significant(all P<0.05).The total effective rate of treatment in the study group was higher than that in the control group,the difference was statistically significant(P<0.05).Conclusion Alprostadil combined with insulin glargine can play a synergistic role in the treatment of diabetic nephropathy,reduce blood glucose levels,improve renal function levels,and improve clinical efficacy through different mechanisms.
AlprostadilInsulin glargineDiabetic nephropathyBlood glucose levelRenal function
维普
万方数据
